A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B‐cell lymphoma

Polatuzumab vedotin (pola) is a CD79b‐targeted antibody‐drug conjugate delivering a potent antimitotic agent (monomethyl auristatin E) to B cells. This was an open‐label, single‐arm study of pola 1.8 mg/kg, bendamustine 90 mg/m(2), rituximab 375 mg/m(2) (pola + BR) Q3W for up to six cycles in patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Terui, Yasuhito, Rai, Shinya, Izutsu, Koji, Yamaguchi, Motoko, Takizawa, Jun, Kuroda, Junya, Ishikawa, Takayuki, Kato, Koji, Suehiro, Youko, Fukuhara, Noriko, Ohmine, Ken, Goto, Hideki, Yamamoto, Kazuhito, Kanemura, Nobuhiro, Ueda, Yasunori, Ishizawa, Kenichi, Kumagai, Kyoya, Kawasaki, Atsuko, Saito, Tomohisa, Hashizume, Misato, Shibayama, Hirohiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253277/
https://www.ncbi.nlm.nih.gov/pubmed/33942442
http://dx.doi.org/10.1111/cas.14937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253277/
https://www.ncbi.nlm.nih.gov/pubmed/33942442
http://dx.doi.org/10.1111/cas.14937

Ejemplares similares